Drug Profile
Stenoparib - Allarity Therapeutics
Alternative Names: 2X-121; 2X-121/PARPi; E-7449; MGI 25036Latest Information Update: 03 Apr 2024
Price :
$50
*
At a glance
- Originator Eisai Co Ltd
- Developer Allarity Therapeutics
- Class Antineoplastics; Antivirals; Isoindoles; Pyridazines; Quinazolines; Small molecules
- Mechanism of Action Poly(ADP-ribose) polymerase 1 inhibitors; Poly(ADP-ribose) polymerase 2 inhibitors; Tankyrase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Breast cancer; Ovarian cancer
- Phase I/II Solid tumours
- Preclinical COVID 2019 infections
- No development reported B-cell lymphoma; Neuroblastoma; Renal cancer; Sarcoma
Most Recent Events
- 27 Mar 2024 Allarity Therapeutics announces intention of registration Stenoparib for Ovarian cancer
- 27 Mar 2024 Efficacy data from phase-II PREDICT 2X-121 trial in Ovarian cancer released by Allarity Therapeutics
- 20 Feb 2023 Phase-I clinical trials in Solid tumours (Monotherapy, Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT05571969)